Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
NCT ID | NCT06589804 |
Title | Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment |
Recruitment | Recruiting |
Gender | both |
Phase | Phase III |
Variant Requirements | Yes |
Sponsors | National Cancer Institute (NCI) |
Indications | |
Therapies | |
Age Groups: | adult | senior |
Covered Countries | USA |